Trevi Therapeutics: Big Cough Data, Bigger Execution Risk [Seeking Alpha]
Trevi Therapeutics, Inc. (TRVI)
Company Research
Source: Seeking Alpha
TRVI's nalbuphine shows consistent efficacy in Phase 2 trials, but long-term effectiveness, side effects, and commercial potential remain uncertain. Competition from GSK's camlipixant and regulatory risks, alongside a rich $1.2B valuation for a pre-Phase 3, single-asset company, warrant caution. I initiate a 'Hold' rating on TRVI, citing high binary risk, execution challenges, and suitability only for risk-tolerant, barbell portfolios. SewcreamStudio/iStock via Getty Images Introduction This is my first look at Trevi Therapeutics ( TRVI Trevi is developing nalbuphine ER , or Haduvio, for chronic cough. Specifically, cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). BELLUS Health immediately This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it
Show less
Read more
Impact Snapshot
Event Time:
TRVI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRVI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRVI alerts
High impacting Trevi Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TRVI
News
- Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial OfficerPR Newswire
- Trevi Therapeutics (NASDAQ:TRVI) was upgraded by analysts at B. Riley to a "strong-buy" rating.MarketBeat
- Trevi Therapeutics (NASDAQ:TRVI) had its "outperform" rating reaffirmed by analysts at Leerink Partners.MarketBeat
- How Trevi Therapeutics' (TRVI) Phase 3 Progress and Fresh Funding May Influence Investor Expectations [Yahoo! Finance]Yahoo! Finance
- Trevi Therapeutics (TRVI): Assessing Valuation After Clinical Program Advances and Cash Runway Extension [Yahoo! Finance]Yahoo! Finance
TRVI
Earnings
- 11/13/25 - Beat
TRVI
Sec Filings
- 12/5/25 - Form 8-K
- 12/3/25 - Form 4
- 11/14/25 - Form SCHEDULE
- TRVI's page on the SEC website